How an ‘experimental arthritis drug’ could help treat Covid-19
Otilimab given to Manchester man as UK clinical trial kicks off
A new drug developed to treat rheumatoid arthritis may be given to the most seriously ill Covid-19 patients, if a clinical trial now under way in Manchester proves successful.
Farhan Hamid, 41, has become the first British coronavirus patient to receive the drug, called otilimab, as part of a study run by Manchester Royal Infirmary.
“The research aims to establish whether otilimab can treat severe lung disease developed as a result of Covid-19,” says Sky News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Dr Andy Martin, who is running the trial, said Hamid, from south Manchester, had been enrolled in the study because he was experiencing severe difficulty breathing. The experimental drug could “ease the effect of coronavirus on the lungs, dampening the impact of the virus on the immune system”, Martin explained.
Funded by the drug’s manufacturer, Glaxo SmithKline (GSK), the trial has “been given urgent public health research status by the Department of Health and Social Care”, the Daily Mirror reports.
Hospitals from all over the world, including five in the UK, will eventually take part in the tests, which will involve a total of 800 patients. Trials have already begun in the US.
“Those taking part will be allocated into two groups at random, with half receiving a one-hour, single infusion of otilimab,” says the Daily Mail. The other group will get “placebo intravenous therapy, in addition to standard care”.
Christopher Corsico of GSK said the drug is believed to help patients who are experiencing the most severe reaction to Covid-19.
“We know that some Covid-19 patients experience an overreaction of their immune system - sometimes referred to as cytokine storm - which can lead to hospitalisation or death,” he said.
“We believe that otilimab might be able to help counter or calm this process.”
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Why is Bluey such a cultural phenomenon?
In the Spotlight Kids are obsessed — but parents get just as much out of the show, if not more
By Anya Jaremko-Greenwold, The Week US Published
-
Is it actually economical to fly basic economy?
The Explainer Airlines have placed so many restrictions on basic economy, you may wonder if it's even worth the savings anymore
By Becca Stanek, The Week US Published
-
So bad, so good: the best worst movies
The Week Recommends These films are as enjoyable as they are terrible
By Anya Jaremko-Greenwold, The Week US Published
-
Immunotherapy and hay fever
The Explainer Research shows that the treatment could provide significant relief from symptoms for many hay fever sufferers
By Richard Windsor, The Week UK Published
-
Pros and cons of universal health care
Pros and Cons A medical system that serves everyone comes with its own costs, and they're not only financial
By Rebecca Messina, The Week UK Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Martha's Rule: patients given right to urgent second opinion
The Explainer Hospitals in England will launch new scheme that will allow access to a rapid treatment review
By Richard Windsor, The Week UK Published
-
The contaminated blood scandal
The Explainer Widely regarded as the worst treatment disaster in the history of the NHS, the public inquiry is due to publish its report in May
By The Week UK Published
-
Can Britain's dental crisis be fixed?
The Explainer New proposals include more money for dentists working in under-served areas
By Richard Windsor, The Week UK Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published